(Total Views: 611)
Posted On: 05/05/2022 2:00:26 PM
Post# of 154873
Digging the pps appreciation this week (obviously). Would love to see this slow crawl continue as we approach the NASH conference.
I would hope shorts are beginning to get gun-shy because they've been making the "LL doesn't work" argument for a long time purely based on the FDA's suppression and unconscionable lack of support for Cytodyn. But with each passing day, and with each peer-reviewed paper, with each article, and the fact we're presenting data at a huge NASH conference, it should be pretty ****ing obvious to all that our drug definitely works and has enormous unlocked value.
Unexpected news could hit at anytime. Clinical holds lifted? Partnership announcement? Brazil success? New CEO? Surprise EUA?
Short at your peril.
I would hope shorts are beginning to get gun-shy because they've been making the "LL doesn't work" argument for a long time purely based on the FDA's suppression and unconscionable lack of support for Cytodyn. But with each passing day, and with each peer-reviewed paper, with each article, and the fact we're presenting data at a huge NASH conference, it should be pretty ****ing obvious to all that our drug definitely works and has enormous unlocked value.
Unexpected news could hit at anytime. Clinical holds lifted? Partnership announcement? Brazil success? New CEO? Surprise EUA?
Short at your peril.
(20)
(0)
